Skip to main content
Biotage logo

Biotage — Investor Relations & Filings

Ticker · BIOT ISIN · SE0000454746 LEI · 529900SR87NBUKX74L58 ST Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2008-10-31 Interim / Quarterly Rep…
Country SE Sweden
Listing ST BIOT

About Biotage

https://www.biotage.com/

Biotage is a global life science company specializing in separation and purification technologies. It provides systems, consumables, and intelligent workflow solutions for customers in drug discovery and development, analytical testing, and diagnostics. The company's portfolio supports a wide range of applications, including medicinal chemistry, peptide synthesis, biomolecule purification (proteins, DNA, oligonucleotides), and automated sample preparation. Key technologies are applied in flash chromatography and analytical testing for clinical, forensic, and environmental samples. Biotage focuses on streamlining laboratory processes to advance scientific research and human health.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2008
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport januari - september 2008' (Interim Report January - September 2008) for Biotage AB. It contains comprehensive financial statements, including income statements, balance sheet summaries, cash flow analysis, and detailed management commentary on business performance for the third quarter and the first nine months of 2008. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. 9M 2008
2008-10-31 Swedish
Interim / Quarterly Report 2008
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January - September 2008' and contains comprehensive financial statements, including income statements, balance sheet items, cash flow analysis, and detailed business area performance (Discovery Chemistry and Biosystems). It provides actual financial data and analysis for the specified period, meeting the criteria for an Interim/Quarterly Report (IR). It is not an announcement of a report, as it contains the full content of the report itself. 9M 2008
2008-10-31 English
Board/Management Information 2008
Board/Management Information Classification · 99% confidence The document is a press release from Biotage AB dated October 17, 2008. The primary content announces the formation of the Nomination Committee which will prepare proposals for the election of the Board of Directors and Chairman before the Annual General Meeting (AGM) in 2009. This content directly relates to the governance and preparation for the AGM, specifically concerning board nominations and shareholder voting matters. While it mentions the AGM, it is not the AGM presentation itself (AGM-R) or the proxy materials (DEF 14A/PSI). It is an announcement regarding the process leading up to the AGM concerning board composition, which falls under Governance Information (CGR) or potentially a specific aspect of Board/Management Information (MANG). Given the focus on the Nomination Committee preparing proposals for the election of the Board, CGR (Governance Information) is the most appropriate fit, as it deals with internal rules and board structure preparation, although MANG is also closely related. Since it is a formal announcement about the governance structure preparing for elections, CGR is selected.
2008-10-17 English
AGM Information 2008
AGM Information Classification · 95% confidence The document is a press release from Biotage AB dated October 17, 2008. The main subject is the formation of a 'Valberedning' (Nomination Committee) whose task is to prepare for the election of the board of directors, chairman, and remuneration issues ahead of the Annual General Meeting (AGM) in 2009. This content directly relates to the preparation and governance surrounding the AGM, specifically concerning board composition and related matters. This aligns best with the 'AGM Information' category (AGM-R), which covers presentations and materials shared during the AGM, and by extension, preparatory materials for it. It is not a full financial report (10-K, IR), an earnings release (ER), or a management change announcement (MANG).
2008-10-17 Swedish
M&A Activity 2008
M&A Activity Classification · 99% confidence The document is a press release dated October 1, 2008, announcing a significant corporate transaction: Biotage is divesting its Biosystems division to QIAGEN. This involves the sale of assets and shares for a specified purchase price, including details about the strategic review that led to the decision. This type of announcement, detailing a major corporate action like a divestiture or acquisition, is best classified as a 'Transaction in Own Shares' (POS) if it involved share buybacks/issuance, or more broadly, a 'Capital/Financing Update' (CAP) if it relates to restructuring or major asset sales impacting capital structure, or potentially a 'Regulatory Filing' (RNS) if it's a mandatory disclosure. Since the core event is the sale/divestiture of a major business unit, which is a significant corporate transaction impacting the company's structure and future focus, 'CAP' (Capital/Financing Update) is a strong candidate, as it relates to capital structure changes resulting from the sale. However, given the nature of the announcement—a definitive agreement for a major asset sale—and the lack of a specific category for M&A activity (TAR is for M&A *proposals* or *bids*), this is a definitive transaction announcement. In many databases, major asset sales/divestitures that are not tender offers fall under general corporate actions. Since the document is a press release detailing the conclusion of a strategic review and the sale of a division, it is a significant corporate event announcement. Given the options, 'CAP' covers financing/capital structure changes resulting from the sale, but 'RNS' (Regulatory Filings) is often used for definitive transaction announcements that don't fit elsewhere. Considering the context of a major strategic shift involving asset disposal, 'CAP' is the most specific fit among the provided options that deal with structural changes, although 'RNS' is a safe fallback. I will lean towards 'CAP' as the divestiture directly impacts the capital structure and future focus, which aligns with financing/capital updates.
2008-10-01 English
M&A Activity 2008
M&A Activity Classification · 99% confidence The document is a press release from Biotage AB announcing the sale of its Biosystems division to QIAGEN. This transaction involves the divestiture of a business segment, which is a significant corporate action related to financing, capital structure, or strategic direction. While it contains financial details (sale price, revenue/profit of the divested unit), its primary nature is an announcement of a major corporate transaction (divestiture/sale of a division). This fits best under 'Capital/Financing Update' (CAP) as it fundamentally alters the company's structure and capital base, or potentially 'Regulatory Filings' (RNS) if it were a mandatory filing, but given the content focuses on the strategic rationale and financial impact of the sale, CAP is the most specific fit among the provided options for a major strategic transaction announcement that isn't a standard periodic report (10-K, IR) or an earnings release (ER). It is not a proxy statement (DEF 14A), a director's dealing (DIRS), or a simple dividend notice (DIV). Since it details the strategic decision and financial outcome of a major asset sale, CAP is appropriate.
2008-10-01 Swedish

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.